Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Have Never Been More Bullish On Medifast, Inc. (MED)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in these filings, which are based on their December 31 holdings, data that is available nowhere else. Should you consider Medifast, Inc. (NYSE:MED) for your portfolio? We’ll look to this invaluable collective wisdom for the answer.

Hedge fund interest in Medifast, Inc. (NYSE:MED) shares was flat at the end of last quarter. This is usually a negative indicator. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Liberty Oilfield Services Inc. (NYSE:LBRT), CRISPR Therapeutics AG (NASDAQ:CRSP), and WestAmerica Bancorp. (NASDAQ:WABC) to gather more data points.

Why do we pay any attention at all to hedge fund sentiment? Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.5% through March 12, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

AQR CAPITAL MANAGEMENT

Cliff Asness of AQR Capital Management

Let’s view the latest hedge fund action surrounding Medifast, Inc. (NYSE:MED).

How are hedge funds trading Medifast, Inc. (NYSE:MED)?

At the end of the fourth quarter, a total of 22 of the hedge funds tracked by Insider Monkey were long this stock, a change of 0% from the previous quarter. By comparison, 16 hedge funds held shares or bullish call options in MED a year ago. With hedgies’ capital changing hands, there exists a select group of notable hedge fund managers who were upping their holdings significantly (or already accumulated large positions).

MED_apr2019

According to Insider Monkey’s hedge fund database, Renaissance Technologies, managed by Jim Simons, holds the biggest position in Medifast, Inc. (NYSE:MED). Renaissance Technologies has a $123.8 million position in the stock, comprising 0.1% of its 13F portfolio. The second most bullish fund manager is Arrowstreet Capital, led by Peter Rathjens, Bruce Clarke and John Campbell, holding a $25.9 million position; 0.1% of its 13F portfolio is allocated to the stock. Other members of the smart money that hold long positions include Israel Englander’s Millennium Management, Joel Ramin’s 12 West Capital Management and Cliff Asness’s AQR Capital Management.

Judging by the fact that Medifast, Inc. (NYSE:MED) has experienced falling interest from hedge fund managers, we can see that there is a sect of funds who sold off their full holdings in the third quarter. Intriguingly, Steven Boyd’s Armistice Capital dropped the largest position of the 700 funds watched by Insider Monkey, worth about $5.3 million in stock, and Steve Cohen’s Point72 Asset Management was right behind this move, as the fund sold off about $5 million worth. These transactions are intriguing to say the least, as total hedge fund interest stayed the same (this is a bearish signal in our experience).

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Medifast, Inc. (NYSE:MED) but similarly valued. We will take a look at Liberty Oilfield Services Inc. (NYSE:LBRT), CRISPR Therapeutics AG (NASDAQ:CRSP), WestAmerica Bancorp. (NASDAQ:WABC), and Aimmune Therapeutics Inc (NASDAQ:AIMT). This group of stocks’ market valuations match MED’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
LBRT 12 75972 4
CRSP 11 89245 -5
WABC 5 4479 1
AIMT 16 188597 -2
Average 11 89573 -0.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 11 hedge funds with bullish positions and the average amount invested in these stocks was $90 million. That figure was $270 million in MED’s case. Aimmune Therapeutics Inc (NASDAQ:AIMT) is the most popular stock in this table. On the other hand WestAmerica Bancorp. (NASDAQ:WABC) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks Medifast, Inc. (NYSE:MED) is more popular among hedge funds. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Hedge funds were also right about betting on MED, though not to the same extent, as the stock returned 18.7% and outperformed the market as well.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...